April 2010: 55pharma in the press
“Kurier”, one of the largest newspapers in Austria, provides an overview on the scientific and
financial prospects of 55pharma. To download a pdf-version of the full text article (in German),
please click here.
March 2010: 55pharma receives AWS grant
55pharma receives from
Austria Wirtschaftsservice Gesellschaft mbH a capital guarantee grant which can be offered to equity investors in the context of the next financing round.November 2009: Chemiereport on 55pharma’s scientific approach
"Chemiereport" publishes an article on 55pharma’s technological and portfolio perspective. To download a pdf-version of the full text article (in German), please click here.
July 2009: 55pharma receives grant to support preparation for clinical studies
The company receives from JITU – Management auf Zeit des BMWFJ operated by
AWS – Austria Wirtschaftsservice Gesellschaft mbH.
The funding is used to prepare for the clinical studies of the lead compound from the most advanced development program.
Mai 2009: 55pharma in Austrian business press
"GEWINN" on Austrian’s biotech and small-cap pharma community. To download a pdf-version of the full text article (in German), please click here.
January 2009: 55pharma in Austrian business press
"Wirtschaftsblatt" publishes an article on 55pharma’s short to mid-term perspective. To download a pdf-version of the full text article (in German), please click here.
January 2009: 55pharma CEO comments on financial crisis in Austrian business press
"Wirtschaftsblatt", Austria's leading business newspaper, is featuring an article from 55pharma CEO Dr. Leonhardt Bauer on public support for innovative companies in the financial crisis. To download a pdf-version of the full text article (in German), please click here.
December 2008: 55pharma receives grant from Österreichische Forschungsförderungsgesellschaft (FFG)
From
Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency) , Austria's central organization for the promotion of research and innovation, 55pharma was awarded a research grant (BRIDGE program) together with its key scientific cooperation partner in Vienna, the Medical University of Vienna. This grant further strenghtens 55pharma's financial position and enables the conduct of major R&D efforts together with the Medical University of Vienna.December 2008: 55pharma in the press
"Die Presse", a leading newspaper in Austria, elaborates on current treatment options for type-2 diabetes, 55pharma’s development pipeline and its future potential. To download a pdf-version of the full text article (in German language), please click here.
October 2008: 55pharma in the business press
In "Format", a leading business journal in Austria, Dr. Leonhardt Bauer comments on development approach and funding situation. To download a pdf-version of the full text article (in German language), please click here.
June 2008: 55pharma in the business press
In "Der Standard", a leading daily newspaper in Austria, 55pharma’s approach to develop medicines designed to provide new options for diabetes patients has been described. To download a pdf-version of the full text article (in German language), please click here.
June 2008: 55pharma receives grant from the Republic of Austria
From the funding agency "AWS – Austria Wirtschaftsservice Gesellschaft mbH", www.awsg.at, 55pharma has been awarded a grant from the program "Double Equity". The grant totalling EUR 1 million represents a significant milestone in the funding of 55pharma’s development program 2008/09.
March 2008: Interview with 55pharma CEO in the business press
55pharma CEO Dr. Leonhardt Bauer comments on the status of the development pipeline. To download a pdf-version of the full text article (in German language), please click here.
December 2007: 55pharma in Austrian business press
Wirtschaftsblatt, Austria's leading business newspaper, is featuring 55pharma as it reached all milestones of the last financing round. A novel class of anti-diabetic drug candidates is filed for international patent protection. To download a pdf-version of the full text article (in German), please click here.
December 2006: 55pharma receives grant from the government of Lower Austria
In December, 55pharma's application for a grant from the government of Lower Austria was approved. With this grant from funds earmarked for the promotion of business and tourism, Lower Austria contributes substantially to funding 55pharma's research & development activities.
December 2006: 55pharma receives High Tech Company of the Year award from GEWINN
In this year's
GEWINN-Jungunternehmer-Wettbewerb, a renowned competition for young
Austrian companies organized by the Austrian business magazine GEWINN,
55pharma took first place in the category High Tech. On Dec. 6,
55pharma was officially by Austrian Federal Minister Dipl.-Ing. Josef
Pröll. For a picture of the ceremony, please click here. To download a pdf-version of the full text article (in German), please click here.August 2006: 55pharma featured in "WirtschaftsBlatt"
55pharma was selected for the mentoring initiative of Austria's leading business newspaper "WirtschaftsBlatt", teaming up young entrepreneurs with CEOs of Austria's blue chip companies.In August, Dr. Eder met Dr. Gasselsberger, CEO of Oberbank AG. To download a pdf-version of the full text article (in German), please click here.
June 2006: 55pharma receives grant from the Forschungsförderungsgesellschaft
From the
Forschungsförderungsgesellschaft (FFG, Austrian Research Promotion Agency), Austria's central organization for the promotion of research and innovation, 55pharma was awarded a research grant together with its major scientific cooperation partner in Vienna, the Medical University of Vienna. This grant from the program BRIDGE further strenghtens 55pharma's financial position and enables the funding of major R&D efforts together with the Medical University of Vienna.Mai 2006: 55pharma featured in "Chemiereport"
In the Mai issue of the "Chemiereport", one of Austria's leading publications in the field of chemistry, Dr. Bauer and Dr. Eder were interviewed to portray 55pharma. To download a pdf-version of the full text article (in German language), please click here.
April 2006: 55pharma opens laboratory at its new site in Tulln
At the beginning of April, 55pharma put into operation its laboratory at its new site at the Technologiezentrum Tulln (TZT). This kick-off of its in-house R&D activities at the heart of the biotechnology cluster in Tulln - comprising, besides the TZT, the Department for Agrobiotechnology and the degree program Biotechnical Processes of the University for Applied Sciences Wiener Neustadt - allows 55pharma to further strengthen its core competencies in the field of natural products chemistry.
January 2006: 55pharma portrayed in "Der Standard"
In "Der Standard", Austria's leading daily newspaper, 55pharma was portrayed as an example of a highly innovative, young Austrian biotech company. To download a pdf-version of the full text article (in German), please click here.
December 2005: 55pharma receives grant from the Republic of Austria
From the
"aws, Austria Wirtschaftsservice Gesellschaft mbH", a company operating on behalf of the Austrian federal government, 55pharma has been awarded a grant from the program "Seed Financing" totalling EUR 0.5 million. 55pharma's application for this grant has been unanimously approved by the aws' "Seed Financing Board", a jury consisting of renowned international experts in the field of life sciences. In addition, 55pharma has been awarded another 0.5 million EUR from the aws' program Double Equity. These decisions represent major milestones in 55pharma's efforts to secure funds for its R&D program in 2006.October 2005: 55pharma receives grant from the City of Vienna
From the
"ZIT, Zentrum für Innovation und Technologie GmbH", the technology agency of the City of Vienna, 55pharma has been awarded a grant from the program "Innovationssupport". Due to the high evaluation 55pharma has received by the ZIT, the fund has been granted to the maximum degree possible.August 2005: New member of our Advisory Board
55pharma is pleased to announce that Prof. Dr. Gerhard Schlüter, former Member of the Board of Directors and Global Head of Toxicology, BAYER AG, has consented to support 55pharma in all matters regarding drug development as a member of its advisory board.
55pharmaDrug Discovery & Development AGPalais Pálffy, Josefsplatz 61010 Vienna, AustriaTZT, Technopark 13430 Tulln, AustriaPhone:Fax:Email: